Updates are available Correction dated 2023-01-31
Click to view Correction: https://doi.org/10.1186/s13058-023-01611-w
-
Authors
Ayeni, Oluwatosin A.
Joffe, Maureen
Mapanga, Witness
Chen, Wenlong Carl
O’Neil, Daniel S.
Phakathi, Boitumelo
Nietz, Sarah
Buccimazza, Ines
Čačala, Sharon
Stopforth, Laura W.
Jacobson, Judith S.
Crew, Katherine D.
Neugut, Alfred I.
Ramiah, Duvern
Ruff, Paul
Cubasch, Herbert
Chirwa, Tobias
McCormack, Valerie
Micklesfield, Lisa K.
Norris, Shane A.
-
Funding
Funding for this research was provided by:
NIH/NCI
The South African Medical Research Council/University of the Witwatersrand Common Epithelial Cancer Research Center
Cancer Association of South Africa
- License Information
-
More Information
Article History
Received: 22 April 2022
Accepted: 6 January 2023
First Online: 23 January 2023
Change Date: 31 January 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13058-023-01611-w
Declarations
:
: The SABCHO Study was approved by the University of the Witwatersrand Human Research Ethics Committee (Approval Number: Ml50351, dated: 6th May 2015, recertified M1911203 dated 28 January 2020), the University of KwaZulu-Natal Biomedical Research Committee, BF080/15, and the Institutional Review Board of Columbia University (protocol number AAAQ1359, dated 1st January 2016). All women provided written or fingerprint-confirmed informed consent.
: Not applicable.
: AIN has consulted for Otsuka, Eisai, GlaxoSmithKline, United Biosource Corp., and Hospira. He has grant support from Otsuka. He is on the medical advisory board of EHE Intl. All other authors declare that they have no competing interest.
